Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have shown remarkable therapeutic efficacy in multiple malignancies26, but their effectiveness in pancreatic cancer is limited26. This evidence concerns the gene PDCD1 and familial pancreatic carcinoma.